FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2605089332> ?p ?o ?g. }

• W2605089332 abstract "573 Background: ER cross-activation by growth-factor signalling causes resistance to endocrine therapy (ET) in patients (pts) with Her2-positive MBC. Moreover, low levels of Her2-expression (Her2 1+; Her2 2+ without gene amplification), may result in reduced efficacy of ET in early breast cancer pts. In a recently published study, these tumours had a less favourable outcome as compared to tumours with a Her2-score of 0. Here, we investigated if low levels of Her2-expression could predict for shorter progression-free survival (PFS) in MBC pts on ET. Methods: PFS on first-line ET was chosen as primary endpoint and estimated with the Kaplan-Meier method. To test for differences between PFS curves, the log-rank test was used. Association of the following variables with PFS was investigated: low Her2-expression, grading, level of ER-expression, progesterone-receptor status, Ki67 (cut-off ≤20%), prior adjuvant ET, and presence of visceral metastases. For an estimated superiority of 40% in terms of PFS in favour of the Her2-negative group, a sample of 130 pts in two groups was needed in order to rule out the null-hypothesis with a 80% power and a two-sided α of 0.025. Results: A total number of 320 ER-positive MBC pts were identified from a breast cancer database; 170 pts were available for this analysis. Median PFS on first-line ET was 11 months (m) (8.56-13.44), corresponding numbers for second-line were 6 m (4.65-7.36), and third-line 4 m (1.52-6.48), respectively; median OS from diagnosis of MBC was 58 m (48.15-67.86). None of the variables investigated were significantly associated with first-line PFS. Second-line PFS, however, was significantly shorter in pts with grade 3 tumours and prior adjuvant ET; a trend towards shorter PFS was observed in high proliferating tumours. Conclusions: In this chart review, low levels of Her2 expression did not predict for shorter PFS in pts receiving ET; PFS in different treatment lines was well in line with data from clinical trials. High tumour grading and prior adjuvant ET were associated with accelerated onset of resistance, rendering those patients candidates for early combination of ET with targeted treatment approaches." @default.
• W2605089332 created "2017-04-14" @default.
• W2605089332 creator A5001256203 @default.
• W2605089332 creator A5009951883 @default.
• W2605089332 creator A5013889354 @default.
• W2605089332 creator A5017092675 @default.
• W2605089332 creator A5019454470 @default.
• W2605089332 creator A5025877193 @default.
• W2605089332 creator A5032289640 @default.
• W2605089332 creator A5036368628 @default.
• W2605089332 creator A5036695602 @default.
• W2605089332 creator A5039578906 @default.
• W2605089332 creator A5041466806 @default.
• W2605089332 creator A5062590114 @default.
• W2605089332 creator A5076784790 @default.
• W2605089332 creator A5077961608 @default.
• W2605089332 creator A5087875400 @default.
• W2605089332 date "2013-05-20" @default.
• W2605089332 modified "2023-09-27" @default.
• W2605089332 title "Low HER2-expression to predict impaired activity of endocrine therapy in patients with estrogen-receptor (ER) positive metastatic breast cancer (MBC)." @default.
• W2605089332 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.573" @default.
• W2605089332 hasPublicationYear "2013" @default.
• W2605089332 type Work @default.
• W2605089332 sameAs 2605089332 @default.
• W2605089332 citedByCount "0" @default.
• W2605089332 crossrefType "journal-article" @default.
• W2605089332 hasAuthorship W2605089332A5001256203 @default.
• W2605089332 hasAuthorship W2605089332A5009951883 @default.
• W2605089332 hasAuthorship W2605089332A5013889354 @default.
• W2605089332 hasAuthorship W2605089332A5017092675 @default.
• W2605089332 hasAuthorship W2605089332A5019454470 @default.
• W2605089332 hasAuthorship W2605089332A5025877193 @default.
• W2605089332 hasAuthorship W2605089332A5032289640 @default.
• W2605089332 hasAuthorship W2605089332A5036368628 @default.
• W2605089332 hasAuthorship W2605089332A5036695602 @default.
• W2605089332 hasAuthorship W2605089332A5039578906 @default.
• W2605089332 hasAuthorship W2605089332A5041466806 @default.
• W2605089332 hasAuthorship W2605089332A5062590114 @default.
• W2605089332 hasAuthorship W2605089332A5076784790 @default.
• W2605089332 hasAuthorship W2605089332A5077961608 @default.
• W2605089332 hasAuthorship W2605089332A5087875400 @default.
• W2605089332 hasConcept C121608353 @default.
• W2605089332 hasConcept C126322002 @default.
• W2605089332 hasConcept C143998085 @default.
• W2605089332 hasConcept C2775930923 @default.
• W2605089332 hasConcept C2777164284 @default.
• W2605089332 hasConcept C2780482068 @default.
• W2605089332 hasConcept C46699223 @default.
• W2605089332 hasConcept C530470458 @default.
• W2605089332 hasConcept C71315377 @default.
• W2605089332 hasConcept C71924100 @default.
• W2605089332 hasConcept C84606932 @default.
• W2605089332 hasConceptScore W2605089332C121608353 @default.
• W2605089332 hasConceptScore W2605089332C126322002 @default.
• W2605089332 hasConceptScore W2605089332C143998085 @default.
• W2605089332 hasConceptScore W2605089332C2775930923 @default.
• W2605089332 hasConceptScore W2605089332C2777164284 @default.
• W2605089332 hasConceptScore W2605089332C2780482068 @default.
• W2605089332 hasConceptScore W2605089332C46699223 @default.
• W2605089332 hasConceptScore W2605089332C530470458 @default.
• W2605089332 hasConceptScore W2605089332C71315377 @default.
• W2605089332 hasConceptScore W2605089332C71924100 @default.
• W2605089332 hasConceptScore W2605089332C84606932 @default.
• W2605089332 hasLocation W26050893321 @default.
• W2605089332 hasOpenAccess W2605089332 @default.
• W2605089332 hasPrimaryLocation W26050893321 @default.
• W2605089332 hasRelatedWork W1560902026 @default.
• W2605089332 hasRelatedWork W1569314840 @default.
• W2605089332 hasRelatedWork W1999946604 @default.
• W2605089332 hasRelatedWork W2062710069 @default.
• W2605089332 hasRelatedWork W2102425509 @default.
• W2605089332 hasRelatedWork W2155171887 @default.
• W2605089332 hasRelatedWork W2222265211 @default.
• W2605089332 hasRelatedWork W2326697016 @default.
• W2605089332 hasRelatedWork W2414093414 @default.
• W2605089332 hasRelatedWork W2414549503 @default.
• W2605089332 hasRelatedWork W2593860699 @default.
• W2605089332 hasRelatedWork W2594964516 @default.
• W2605089332 hasRelatedWork W2605660842 @default.
• W2605089332 hasRelatedWork W2761572819 @default.
• W2605089332 hasRelatedWork W2901027329 @default.
• W2605089332 hasRelatedWork W2943903238 @default.
• W2605089332 hasRelatedWork W2943958617 @default.
• W2605089332 hasRelatedWork W3135453266 @default.
• W2605089332 hasRelatedWork W3172431764 @default.
• W2605089332 hasRelatedWork W3172568239 @default.
• W2605089332 isParatext "false" @default.
• W2605089332 isRetracted "false" @default.
• W2605089332 magId "2605089332" @default.
• W2605089332 workType "article" @default.